Miri Ben-Ami

Aposense Ltd. engages in the provision of proprietary conjugates. It offers platform technology which comprises the rational design of small molecular moieties with the increased affinity to the cell membranes imparting the conjugates compound with improved drug properties such as extended life span oral bioavailabity and selective at target site. The company was founded by Ilan Ziv and Jacob Gottenstein on October 9, 1996 and is headquartered in Petach-Tikva, Israel.

Part of Immune Pharmaceuticals, Inc., Immune Pharmaceuticals Ltd. develops pharmaceutical products for the treatment of cancer and pain. The company is based in Herzliya-Pituach, Israel. Immune Pharmaceuticals was acquired by EpiCept Corp. on August 26, 2013 for $21.43 million.

Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. It is also developing NanoCyclo, a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (AD) and psoriasis. The company was founded by Daniel Gedeon Teper on March 9, 1993 and is headquartered in Englewood Cliffs, NJ.